NCT05569720View on ClinicalTrials.gov

First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

June 24, 2022

Study Completion Date

June 24, 2022

Conditions
Stroke
Interventions
DRUG

ApTOLL

"ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."

Trial Locations (1)

28006

Clinical Pharmacology Department. Hospital Universitario de La Princesa, Madrid

All Listed Sponsors
collaborator

Centro para el Desarrollo Tecnológico Industrial

UNKNOWN

lead

aptaTargets S.L.

INDUSTRY